AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32321955
Drug: Control teeth
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control teeth (no treatment)
Trial: 34529811
Drug: Caffeinated gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated gum (4 mg/kg)
Trial: 35255814
Drug: Near point-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Near point-of-care CT and NG testing and treatment intervention
Trial: 32658797
Drug: Dexmedetomidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine plus ropivacaine (1 μg kg−1 dexmedetomidine and 0.25% ropivacaine)
Trial: 33451627
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1000 mg)
Trial: 32046665
Drug: Upfront combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront combination therapy
Trial: 35235834
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention with just-in-time adaptive intervention (JITAI) promoting low-level physical activity and exercise, including access to activity tracking and goal setting through a mobile application, and weekly activity summaries via email.
Trial: 34729682
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (0.6 mg)
Trial: 33608239
Drug: FDA-approved new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved new generation drug-eluting stent followed by guideline-recommended DAPT duration (3 or 6 months)
Trial: 34034268
Drug: Midodrine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (15 mg daily) and albumin (20 g weekly) in group‐A (Gp‐A)
Trial: 34034268
Drug: Albumin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (20 g weekly) alone in group‐B (Gp‐B)
Trial: 33872448
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral antibiotics with mechanical bowel preparation (MBP)
Trial: 33872448
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral antibiotics without mechanical bowel preparation (control)
Trial: 33872448
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral antibiotics with MBP
Trial: 33872448
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral antibiotics without MBP (control)
Trial: 33057642
Drug: Prehospital plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital plasma administration (2 units of thawed plasma)
Trial: 33057642
Drug: Prehospital plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital plasma administration
Trial: 33352600
Drug: Marine phytoplankton
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine phytoplankton 2.55 mg·d‐1
Trial: 33352600
Drug: Marine phytoplankton
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine phytoplankton 5.1 mg·d‐1
Trial: 34744149
Drug: Ivabradine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (20 mg)
Trial: 34744149
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (20 mg)
Trial: 38587333
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid
Trial: 35460392
Drug: AMG 986
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 986 (up to 650 mg/day)
Trial: 33653320
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Serratiopeptidase
Trial: 33653320
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Paracetamol
Trial: 36088057
Drug: Prolutex (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolutex (25 mg daily)
Trial: 36088057
Drug: Crinone (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone (90 mg daily)
Trial: 32062671
Drug: Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab combination therapy
Trial: 32062671
Drug: Cetuximab as
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab as an alternative treatment
Trial: 32062671
Drug: Cetuximab treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab treatment for ≥10 months
Trial: 33990437
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (placebo group)
Trial: 35871718
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa (NS) oil supplementation (2 g/daily for 8 weeks)
Trial: 32197620
Drug: CHF6001 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 800 μg BID
Trial: 32197620
Drug: CHF6001 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 1600 μg BID
Trial: 32561266
Drug: HTX-011 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 400 mg bupivacaine/12 mg meloxicam
Trial: 32561266
Drug: HTX-011 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 400 mg bupivacaine/12 mg meloxicam with 50 mg ropivacaine
Trial: 32561266
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride (HCl) 125 mg injection
Trial: 32889881
Drug: Novel Oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel Oral Anticoagulant (NOAC) therapy
Trial: 33285008
Drug: Fresh frozen
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh frozen plasma (15 ml.kg−1)
Trial: 32527676
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality based cognitive behavioral therapy (VR‐CBT)
Trial: 33839552
Drug: Aromatherapy (inhalation)
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (inhalation)
Trial: 35253448
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (450 mg/d)
Trial: 35253448
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (450 mg/d)
Trial: 35253448
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (450 mg/d)
Trial: 35218628
Drug: Pinggan Jiangya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinggan Jiangya decoction combined with penetrating needling at Baihui (GV20) once daily for 8 weeks
Trial: 35218628
Drug: Pinggan Jiangya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinggan Jiangya decoction once daily for 8 weeks
Trial: 33418362
Drug: CADSS-6 (6-item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CADSS-6 (6-item version of the Clinician-Administered Dissociative States Scale)
Trial: 33415915
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) as add-on treatment
Trial: 33751652
Drug: Personal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal oral hygiene (pOH) at daily intervals (12-24 hours)
Trial: 33751652
Drug: Personal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal oral hygiene (pOH) at extended intervals (48 hours)
Trial: 33474858
Drug: Aspirin desensitization
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin desensitization
Trial: 34506358
Drug: Daily mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mobile reporting
Trial: 34506358
Drug: Daily swabbing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily swabbing arm
Trial: 33212256
Drug: Favipiravir (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir (1800 mg BID on day 1 and 800 mg BID from days 2-14) plus standard supportive care
Trial: 36462528
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose primaquine combined with artemether-lumefantrine
Trial: 36462528
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose primaquine combined with dihydroartemisinin-piperaquine
Trial: 32037149
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin 200 mg/kg/day for 8 weeks
Trial: 33060432
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) ketamine 0.5 mg/kg
Trial: 33060432
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine 1 mg/kg
Trial: 36271428
Drug: Multimodal chiropractic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal chiropractic care including spinal manipulation, education, exercise, self-management advice, and myofascial therapies over 8 weeks, twice weekly sessions
Trial: 33615628
Drug: TAS0313 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0313 (9 mg)
Trial: 33615628
Drug: TAS0313 (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0313 (27 mg)
Trial: 33615628
Drug: TAS0313 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0313 (9 mg and 27 mg)
Trial: 35120861
Drug: Tactile, kinesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactile, kinesthetic and oral stimulation (T + K + OS)
Trial: 34024541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three CT slices (L2, L3, L4)
Trial: 33397432
Drug: PVP-I nasal
RxNorm normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVP-I nasal spray at 0.5%
Trial: 33397432
Drug: PVP-I nasal
RxNorm normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVP-I nasal spray at 0.6%
Trial: 33397432
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water through nasal spray (placebo)
Trial: 35830988
Drug: Low-dose low-molecular-weight-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose low-molecular-weight-heparin (LMWH) therapy
Trial: 35830988
Drug: High-dose low-molecular-weight-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose low-molecular-weight-heparin (LMWH) therapy
Trial: 35830988
Drug: High-dose low-molecular-weight-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose low-molecular-weight-heparin (LMWH) with aspirin
Trial: 35503305
Drug: SBIRT Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SBIRT Intervention for Trauma Patients (SITP) - a 15-minute session with elements of cognitive behavioral therapy techniques
Trial: 35748760
Drug: The Daily
RxNorm normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Daily Mile (TDM) - a daily one mile outdoor run/walk performed at a self‐selected pace during school hours
Trial: 35748760
Drug: The Daily
RxNorm normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Daily Mile (TDM)
Trial: 35546449
Drug: HDV-insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HDV-insulin lispro with a 10% decrease in BaI dose
Trial: 35546449
Drug: HDV-insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HDV-insulin lispro with a 40% decrease in BaI dose
Trial: 33048394
Drug: Screening attendance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening attendance (at least twice)
Trial: 34715000
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable antipsychotics (LAI)
Trial: 34715000
Drug: Oral atypical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atypical antipsychotics (OAA)
Trial: 33786649
Drug: Azithromycin (AZI)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZI) 500 mg/day for 3 days
Trial: 34330456
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (2000 mg/d)
Trial: 34118498
Drug: IVY intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVY intervention (vaccine education and quality improvement program)
Trial: 34407695
Drug: Sachet water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sachet water (46% consumption); bottled water (100%, n=2); chlorine-based disinfectants for water treatment
Trial: 33559648
Drug: Skin prick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin prick testing and measurement of volatile organic compounds in exhaled breath
Trial: 32147075
Drug: Curcuminoids (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (500 mg plus 5 mg piperine per day for 8 weeks)
Trial: 32436902
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids 500 mg (EPA/DHA 180/120 mg), BD daily for 1 month
Trial: 32325043
Drug: NOACs (nonvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs (nonvitamin K antagonist oral anticoagulants)
Trial: 35447066
Drug: Met52 fungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Met52 fungal spray
Trial: 36253611
Drug: Anti-tau monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-tau monoclonal antibody gosuranemab
Trial: 34454786
Drug: Ro‐VLP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro‐VLP vaccine (21 μg) in adults
Trial: 34454786
Drug: Ro‐VLP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro‐VLP vaccine (7 μg or 21 μg) in toddlers
Trial: 34454786
Drug: Ro‐VLP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro‐VLP vaccine (2.5 μg, 7 μg or 21 μg) in infants
Trial: 34454786
Drug: Oral Rotarix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Rotarix (2 doses) in infants
Trial: 36572280
Drug: Total neoadjuvant
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total neoadjuvant therapy (TNT)
Trial: 32270474
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine
Trial: 32270474
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL saline bilaterally and an elastomeric pump containing saline
Trial: 33008432
Drug: Motor Imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor Imagery practice combined with routine physical therapy (MIp)
Trial: 33008432
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving physical therapy alone (CON)
Trial: 35351144
Drug: Inulin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (16 g/day) with dietary advice for 3 months
Trial: 33924761
Drug: W. cibaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: W. cibaria CMU tablets administered once daily for 8 weeks before bedtime
Trial: 33924761
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily for 8 weeks before bedtime
Trial: 32665367
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (Palforzia)
Trial: 34119410
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping with voice therapy
Trial: 35203045
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (360 µg/d)
Trial: 34108169
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice (equivalent dose of telephone-based sessions)
Trial: 32544119
Drug: Natural topical
RxNorm normalized name: CAPSAICIN 0.025 g in 100 g / LEVOMENTHOL 4 g in 100 g TOPICAL CREAM [XENCARE INFLAMAX NATURAL TOPICAL PAIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural topical skin ointment (aloe vera, honey, and peppermint)
Trial: 32743919
Drug: Strength-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength-based intervention (14 weekly group sessions and 2 bi-weekly follow-up calls)
Trial: 34791160
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy (including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, mineralocorticoid receptor antagonists, and cardiac rehabilitation)
Trial: 32798144
Drug: Combined everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined everolimus plus lanreotide therapy
Trial: 32798144
Drug: Everolimus monotherapy
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus monotherapy
Trial: 33296541
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (GCBT) plus usual care (UC)
Trial: 33881692
Drug: FYM +
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FYM + P'K' + L
Trial: 33881692
Drug: NPK +
RxNorm normalized name: LINER,MASK,NASAL REMZZZS#7A-NPK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPK + L
Trial: 32236718
Drug: Concomitant antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant antiplatelet therapy (APT)
Trial: 35364018
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks for 48 weeks
Trial: 33376150
Drug: GSK2798745 (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2798745 (2.4 mg)
Trial: 33376150
Drug: GSK2798745 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2798745 (5 mg)
Trial: 32361032
Drug: Enhanced Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Family Therapy (ET)
Trial: 32361032
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive behavioral therapy (CBT) family intervention (ST)
Trial: 36178519
Drug: Hybrid rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid rapid maxillary expander (RME) and facemask (FM) treatment
Trial: 33199379
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg/mL added to LIA mixture
Trial: 32441415
Drug: Higher levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher levels of interleukin-1 receptor antagonist (IL-1ra)
Trial: 32441415
Drug: Higher levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher levels of interleukin-2 receptor alpha subunit (IL-2rα)
Trial: 36134648
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus chemotherapy (S + CT group)
Trial: 36134648
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus oral chemotherapy (S + CT group)
Trial: 36134648
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus intravenous chemotherapy (S + CT group)
Trial: 36134648
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (S + CT group)
Trial: 34941035
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support combined with insulin therapy